What is Evonik's Q2 2026 adjusted EBITDA outlook, and what key factors are driving this expectation?

Evonik expects adjusted EBITDA of at least €550 million for Q2 2026 — up from €509 million a year earlier — driven primarily by short-term customer stockpiling (pre-buying) since March, especially in businesses affected by supply chain disruptions from the Middle East war, and higher-than-expected methionine prices. The company explicitly attributes this Q2 strength to 'higher sales volumes in certain businesses' linked to pre-buying behavior and notes that these tailwinds are expected to continue into the second quarter, making it 'the strongest quarter in 2026' before inflationary pressures and rising energy/raw material costs weigh on demand in the second half.

Why did Evonik’s Q1 2026 sales decline 9% year-on-year, and how did its adjusted EBITDA performance compare to forecasts?

Evonik’s Q1 2026 sales fell 9% year-on-year to €3.43 billion, largely due to unfavorable exchange rates, while sales volumes declined by 2% and selling prices by 1%. Despite the sales miss versus consensus (€3.61 billion), adjusted EBITDA came in at €475 million — slightly above the company’s own forecast of around €450 million and also above the S&P Capital IQ analyst consensus of €452 million.

Evonik Expects Q2 Tailwinds from Customer Stockpiling Amid Middle East War Impact

May 8, 2026

Evonik anticipates Q2 market tailwinds driven by customer stockpiling due to Middle East conflict disruptions, with methionine prices rising. Despite a 9% Q1 sales decline, adjusted EBITDA beat forecasts and full-year guidance remains unchanged.

chemweek

2026-05-08

Evonik Expects Q2 Tailwinds from Customer Stockpiling Amid Middle East War Impact

2026-08-04

European Chemical Giants' Q2 Performance Generally Exceeds Expectations

Evonik Expects Q2 Tailwinds from Customer Stockpiling Amid Middle East War Impact

FAQ